Details of the Drug Combinations

General Information of This Drug (ID: DMDYA31)

Drug Name

Pretomanid DMDYA31

Synonyms

PA-824; 187235-37-6; Pretomanid; PA 824; PA824; UNII-2XOI31YC4N; (S)-PA 824; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; 2XOI31YC4N; CHEMBL227875; MMV688755; AK161427; (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine; Pretomanid [USAN:INN]; C14H12F3N3O5; PA-824(Pretomanid); AC1L9UFX; Pretomanid (USAN/INN); MLS006011141; SCHEMBL2983011

Indication

Disease Entry	ICD 11	Status	REF
Tuberculosis	1B10-1B14	Approved	[1]
Mycobacterium infection	1B10-1B21	Phase 3	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Pretomanid + Marizomib	DCDTF3X	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Pretomanid + Idarubicin	DCC13K3	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]
------------------------------------------------------------------------------------

9 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Bedaquiline + Pretomanid	DC08DD6	Bedaquiline	Pulmonary Tuberculosis	[4]
Efavirenz + Pretomanid	DC9WMNX	Efavirenz	Tuberculosis	[5]
Pretomanid + Midazolam	DCJMRR1	Midazolam	Tuberculosis	[6]
Pretomanid + Moxifloxacin	DCW5NJK	Moxifloxacin	Pulmonary Tuberculosis	[4]
Pyrazinamide + Pretomanid	DCA3OI7	Pyrazinamide	Pulmonary Tuberculosis	[4]
Rifampicin + Pretomanid	DCXHPD3	Rifampicin	Tuberculosis	[5]
Bedaquiline + Pretomanid	DCTEABV	Bedaquiline	Pulmonary Tuberculosis	[7]
Pyrazinamide + Pretomanid	DC08G4C	Pyrazinamide	Pulmonary Tuberculosis	[8]
Pyrazinamide + Pretomanid	DCI1QMJ	Pyrazinamide	Tuberculosis, Pulmonary, Drug Sensitive	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 DrugCom(s)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2	ClinicalTrials.gov (NCT02342886) Shortening Treatment by Advancing Novel Drugs. U.S. National Institutes of Health.
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	ClinicalTrials.gov (NCT01215851) Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
5	ClinicalTrials.gov (NCT01571414) Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
6	ClinicalTrials.gov (NCT01768273) Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam
7	ClinicalTrials.gov (NCT01691534) Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z). U.S. National Institutes of Health.
8	ClinicalTrials.gov (NCT01498419) Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)